CollPlant Biotechnologies (CLGN) Competitors $2.77 -0.14 (-4.81%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.80 +0.03 (+1.08%) As of 06:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLGN vs. LUCD, ZJYL, RCEL, OBIO, INO, NSPR, SPAI, HYPR, FONR, and BDMDShould you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Lucid Diagnostics (LUCD), Jin Medical International (ZJYL), Avita Medical (RCEL), Orchestra BioMed (OBIO), Inovio Pharmaceuticals (INO), InspireMD (NSPR), Safe Pro Group (SPAI), Hyperfine (HYPR), Fonar (FONR), and Baird Medical Investment (BDMD). These companies are all part of the "medical equipment" industry. CollPlant Biotechnologies vs. Its Competitors Lucid Diagnostics Jin Medical International Avita Medical Orchestra BioMed Inovio Pharmaceuticals InspireMD Safe Pro Group Hyperfine Fonar Baird Medical Investment Lucid Diagnostics (NASDAQ:LUCD) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Do analysts prefer LUCD or CLGN? Lucid Diagnostics currently has a consensus price target of $3.55, suggesting a potential upside of 195.83%. CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 315.16%. Given CollPlant Biotechnologies' higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Lucid Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of LUCD or CLGN? 74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to LUCD or CLGN? In the previous week, Lucid Diagnostics had 4 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 6 mentions for Lucid Diagnostics and 2 mentions for CollPlant Biotechnologies. Lucid Diagnostics' average media sentiment score of 0.96 beat CollPlant Biotechnologies' score of 0.31 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LUCD or CLGN more profitable? CollPlant Biotechnologies has a net margin of -541.34% compared to Lucid Diagnostics' net margin of -1,476.35%. Lucid Diagnostics' return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,476.35% N/A -120.43% CollPlant Biotechnologies -541.34%-94.08%-68.62% Which has preferable earnings and valuation, LUCD or CLGN? CollPlant Biotechnologies has lower revenue, but higher earnings than Lucid Diagnostics. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$4.35M29.93-$45.53M-$1.19-1.01CollPlant Biotechnologies$510K69.09-$16.61M-$1.13-2.45 Which has more risk and volatility, LUCD or CLGN? Lucid Diagnostics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. SummaryCollPlant Biotechnologies beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks. Get CollPlant Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLGN vs. The Competition Export to ExcelMetricCollPlant BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-2.4521.0831.2626.59Price / Sales69.09356.05436.91155.84Price / CashN/A44.6737.7359.36Price / Book2.838.0910.736.68Net Income-$16.61M-$54.08M$3.27B$265.59M7 Day Performance9.92%-0.41%1.42%0.62%1 Month Performance13.99%6.23%6.21%2.61%1 Year Performance-49.17%10.45%51.81%22.34% CollPlant Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLGNCollPlant Biotechnologies2.8077 of 5 stars$2.77-4.8%$11.50+315.2%-46.6%$37M$510K-2.4570LUCDLucid Diagnostics2.8762 of 5 stars$1.18+1.3%$3.55+202.1%+53.8%$127.46M$4.35M-0.9970ZJYLJin Medical InternationalN/A$0.78-8.1%N/A-71.8%$122.58M$23.50M0.00245RCELAvita Medical1.5649 of 5 stars$4.48-3.8%$12.40+177.1%-51.9%$119.12M$64.25M-2.27130OBIOOrchestra BioMed3.3583 of 5 stars$3.02+16.0%$14.00+364.0%-58.2%$116.90M$2.94M-1.654High Trading VolumeINOInovio Pharmaceuticals4.0842 of 5 stars$1.98+1.3%$8.80+345.6%-65.5%$104.95M$220K-0.76320NSPRInspireMD3.3916 of 5 stars$2.44+1.6%$4.50+84.6%-14.8%$101.76M$7.07M-3.2550Gap DownHigh Trading VolumeSPAISafe Pro Group0.3485 of 5 stars$6.18-9.1%$8.00+29.6%N/A$99.69M$2.17M-7.7111High Trading VolumeHYPRHyperfine1.5471 of 5 stars$1.25flat$1.28+2.7%+18.1%$98.30M$12.89M-2.41190FONRFonar2.5673 of 5 stars$15.53+0.9%N/A-8.4%$96.28M$102.88M12.42480BDMDBaird Medical InvestmentN/A$2.61+9.2%N/AN/A$93.26MN/A0.00N/APositive News Related Companies and Tools Related Companies Lucid Diagnostics Competitors Jin Medical International Competitors Avita Medical Competitors Orchestra BioMed Competitors Inovio Pharmaceuticals Competitors InspireMD Competitors Safe Pro Group Competitors Hyperfine Competitors Fonar Competitors Baird Medical Investment Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access